Alnylam Pharmaceuticals Files Definitive Proxy Statement

Ticker: ALNY · Form: DEF 14A · Filed: Apr 1, 2024 · CIK: 1178670

Sentiment: neutral

Topics: DEF 14A, Proxy Statement, Executive Compensation, Equity Awards, Alnylam Pharmaceuticals

TL;DR

<b>Alnylam Pharmaceuticals filed its DEF 14A proxy statement on April 1, 2024, detailing executive compensation and equity awards.</b>

AI Summary

ALNYLAM PHARMACEUTICALS, INC. (ALNY) filed a Proxy Statement (DEF 14A) with the SEC on April 1, 2024. Alnylam Pharmaceuticals, Inc. filed a Definitive Proxy Statement (DEF 14A) on April 1, 2024. The filing covers the period ending May 16, 2024. The company's fiscal year ends on December 31. Alnylam Pharmaceuticals is in the Pharmaceutical Preparations industry (SIC code 2834). The filing includes details on equity awards granted and their fair values for 2023 and 2022.

Why It Matters

For investors and stakeholders tracking ALNYLAM PHARMACEUTICALS, INC., this filing contains several important signals. This filing provides shareholders with crucial information regarding executive compensation, including the fair value of equity awards, which can influence voting decisions on executive pay proposals. Understanding the details of equity awards and their valuation is important for investors assessing the company's long-term incentive structures and potential dilution.

Risk Assessment

Risk Level: low — ALNYLAM PHARMACEUTICALS, INC. shows low risk based on this filing. The filing is a routine DEF 14A, providing standard disclosures on executive compensation and corporate governance, with no immediate red flags.

Analyst Insight

Shareholders should review the executive compensation details and equity award valuations to inform their voting decisions at the upcoming shareholder meeting.

Key Numbers

Key Players & Entities

FAQ

When did ALNYLAM PHARMACEUTICALS, INC. file this DEF 14A?

ALNYLAM PHARMACEUTICALS, INC. filed this Proxy Statement (DEF 14A) with the SEC on April 1, 2024.

What is a DEF 14A filing?

A DEF 14A is a definitive proxy statement sent to shareholders before annual meetings, covering executive compensation, board nominations, and shareholder votes. This particular DEF 14A was filed by ALNYLAM PHARMACEUTICALS, INC. (ALNY).

Where can I read the original DEF 14A filing from ALNYLAM PHARMACEUTICALS, INC.?

You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by ALNYLAM PHARMACEUTICALS, INC..

What are the key takeaways from ALNYLAM PHARMACEUTICALS, INC.'s DEF 14A?

ALNYLAM PHARMACEUTICALS, INC. filed this DEF 14A on April 1, 2024. Key takeaways: Alnylam Pharmaceuticals, Inc. filed a Definitive Proxy Statement (DEF 14A) on April 1, 2024.. The filing covers the period ending May 16, 2024.. The company's fiscal year ends on December 31..

Is ALNYLAM PHARMACEUTICALS, INC. a risky investment based on this filing?

Based on this DEF 14A, ALNYLAM PHARMACEUTICALS, INC. presents a relatively low-risk profile. The filing is a routine DEF 14A, providing standard disclosures on executive compensation and corporate governance, with no immediate red flags.

What should investors do after reading ALNYLAM PHARMACEUTICALS, INC.'s DEF 14A?

Shareholders should review the executive compensation details and equity award valuations to inform their voting decisions at the upcoming shareholder meeting. The overall sentiment from this filing is neutral.

How does ALNYLAM PHARMACEUTICALS, INC. compare to its industry peers?

Alnylam Pharmaceuticals operates in the Pharmaceutical Preparations sector. This DEF 14A filing is standard for publicly traded companies.

Are there regulatory concerns for ALNYLAM PHARMACEUTICALS, INC.?

The DEF 14A filing is a requirement under the Securities Exchange Act of 1934, mandating disclosure of information for shareholder meetings.

Industry Context

Alnylam Pharmaceuticals operates in the Pharmaceutical Preparations sector. This DEF 14A filing is standard for publicly traded companies.

Regulatory Implications

The DEF 14A filing is a requirement under the Securities Exchange Act of 1934, mandating disclosure of information for shareholder meetings.

What Investors Should Do

  1. Review the detailed breakdown of executive compensation and equity awards.
  2. Analyze the fair value changes of equity awards for both executive and non-executive members.
  3. Understand the implications of equity awards on potential shareholder dilution.

Year-Over-Year Comparison

This filing is a DEF 14A, a routine disclosure, and does not represent a change in the company's financial reporting compared to previous periods.

Filing Stats: 4,526 words · 18 min read · ~15 pages · Grade level 13.5 · Accepted 2024-04-01 16:31:22

Key Financial Figures

Filing Documents

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 49 SAY-ON-PAY – ADVISORY VOTE ON EXECUTIVE COMPENSATION (PROPOSAL 2) 88 RATIFICATION OF APPOINTMENT OF INDEPENDENT AUDITORS (PROPOSAL 3) 90 AUDIT INFORMATION 91 IMPORTANT INFORMATION ABOUT THE ANNUAL MEETING AND VOTING 93 ADDITIONAL INFORMATION AND OTHER MATTERS 99 Table of Contents PROXY STATEMENT SUMMARY This summary highlights important information you will find in this Proxy Statement. As it is only a summary, please review the complete Proxy Statement before you vote. Virtual Annual Meeting Information Date: Thursday, May 16, 2024 Time: 10:30 a.m., Eastern Time Location: Online at www.virtualshareholdermeeting.com/ALNY2024 You will not be able to attend the annual meeting in person. Record Date: March 22, 2024 Voting Items and Board Recommendations Board Recommendation Proposal 1 Election of Four (4) Class II Directors FOR All Nominees Proposal 2 Say-on-Pay—Advisory Vote on Approval of Executive Compensation FOR Proposal 3 Ratification of Independent Auditors FOR All proxies will be voted in accordance with the instructions contained in those proxies. If no choice is specified, the proxies will be voted in favor of the matters set forth in the accompanying Notice of Meeting. On any other matters properly brought before the annual meeting, the named proxies may vote in accordance with their best judgment. Page | 1 Table of Contents How to Vote Vote Right Away Through Advance Voting Methods Vote During Meeting Vote by Internet Using Your Computer Vote by Telephone Vote by Mail Vote During the Meeting Go to www.proxyvote.com and enter the 16-digit control number provided on your proxy card or voting instruction form. Call 1-800-690-6903 or the number on your proxy card or voting instruction form. You will need the 16-digit control number provided on your proxy card or voting instruction form. If you received printed proxy materials, complete, sign an

View Full Filing

View this DEF 14A filing on SEC EDGAR

View on Read The Filing